A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

The technology could be adapted for other common respiratory viruses such as seasonal influenza, avian flu and respiratory syncytial virus (RSV ... also a professor of molecular microbiology and of ...

A Brisbane man who took part in the University of Queensland’s aborted Covid vaccine trial is still returning “false positive” HIV tests four years later.

Respiratory syncytial virus (RSV) is the most common viral pathogen associated ... While the exact causes of pathology during RSV infection are still contested, the data suggest that pulmonary ...

Introduction: Respiratory syncytial virus (RSV) vaccines targeting the fusion glycoprotein ... lung-infiltrating cells, and lung pathology. Results: mG with any adjuvant was ineffective at inducing ...

A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

How to spot RSV symptoms and simple steps to protect yourself - Around 175,000 people over the age of 65 go to their GP about ...

Outlook on RSV, COVID-19 and flu in Canada: Rates of respiratory syncytial virus, or RSV, and COVID-19 are decreasing nationally. The positivity rate for RSV was 8 per cent and COVID-19 was 5.9 ...